JCO is the primary forum of scientific discourse for the American Society of Clinical Oncology (ASCO). Published three times a month, JCO is the foremost peer-reviewed journal focusing on clinical ...

Clinical practice guidelines serve as a guide for doctors and outline appropriate methods of treatment and care. Guidelines can address specific clinical situations (disease-oriented) or use of ...

JCO Journals adhere to the guidelines on authorship established by the International Committee of Medical Journal Editors (ICMJE) statement on the role of Authors and Contributors. According to these ...

PURPOSETo assess whether the integration of PD-1 inhibitor with total neoadjuvant therapy (iTNT) can lead to an improvement in complete responses (CRs) and favors a watch-and-wait (WW) strategy in ...

LBA1001Background: The combination of CDK4/6 inhibitors (CDK4/6i) + endocrine therapy (ET) is the standard first line treatment for HR+, HER2- advanced breast cancer (ABC). While disease progression ...

A randomised, controlled, multicentre trial of imiquimod versus radiotherapy for lentigo maligna. Efficacy and safety of lifileucel, an autologous tumor-infiltrating lymphocyte cell therapy, and ...

Rationale 305: Phase 3 study of tislelizumab plus chemotherapy vs placebo plus chemotherapy as first-line treatment (1L) of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC).

LBA1Background: PARADIGM is the first prospective trial to test the superiority of PAN vs. BEV in combination with standard doublet first-line chemotherapy for patients (pts) with RAS WT mCRC and left ...

3511Background: The combination of PD-1 and CTLA4 blockade has changed the treatment landscape for several cancer types. Although this treatment is highly effective in metastatic mismatch-repair ...

SPECIAL SERIES: DISPARITIES IN CANCER CARE FOR HISPANIC-LATINX PEOPLE ...

Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA.

JUPITER-02: Randomized, double-blind, phase III study of toripalimab or placebo plus gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC). This ...